TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00250835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy, Celecoxib, and Radiation
Description: Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
Study: NCT03514628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The Valsalva strain will be produced using Standard Care techniques

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valsalva Assist Device (VAD)
Description: Use of Valsalva Assist Device (VAD) to generate VM
Study: NCT03550482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ONCOXIN®
Description: Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.
Study: NCT04357821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Intervention
Description: 1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4~2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12~3. MVA/HIV62B (MVA62B) boost at Week 20~4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)~5. ATI with single dose of VRC07 and 10-1074 at Week 34
Study: NCT01335763

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glargine
Description: 10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L
Study: NCT02152852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Intervention
Description: For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
Study: NCT03270735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Snake venom thrombin (Treatment)
Description: Snake venom thrombin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No snake venom thrombin
Study: NCT04036968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study: NCT04414800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Distilled water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1 mg/kg intranasal ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1μg/kg intranasal fentanyl
Study: NCT01553981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tab. Tadalafil 20 mg every other day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Shape , size, color and odor matched Tab. of inert material every other day for 6 months
Study: NCT01201161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham injection
Description: Simulation of intravitreal injection one week before pars plana vitrectomy
Study: NCT01208714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: revascularization
Description: The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
Study: NCT00750633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate otic solution
Description: 4 drops in the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
Study: NCT03320759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy rehabilitation
Description: Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
Study: NCT01681433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Standard therapy: Abiraterone Acetate 1000 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard therapy: Abiraterone Acetate 1000 mg PO daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Standard therapy: Prednisone 10-20 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Standard therapy: Prednisone 10-20 mg PO daily
Study: NCT02820428

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy participants
Description: Semi-structured interview
Study: NCT02931058

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two knee-extension exercise sessions per week.
Description: Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four knee-extension exercise sessions per week.
Description: Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Six knee-extension exercise sessions per week.
Description: Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band.
Study: NCT02803944

Intervention type: DRUG
Intervention: Azithromycin
Study: NCT03070847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Dose: 5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Dose: 10mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride
Description: Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
Study: NCT01358864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once a day (QD) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once a day (QD) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha (IFN)
Description: Pegylated Interferon-alpha for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV) for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV) for 24 or 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin (RBV) for 24 or 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to BI201335 for 24 weeks
Study: NCT01964014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: advagrf
Description: All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat.
Study: NCT05428891

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.
Description: We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.
Description: We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
Study: NCT02285621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized brace versus conventional Boston brace
Description: Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized brace versus conventional Boston brace
Description: Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
Study: NCT02656485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B244
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B244
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B244
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B244
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
Study: NCT02081781

Intervention type: PROCEDURE
Intervention: Probing
Description: A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner.
Study: NCT02210767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Diet
Description: 2 oz. walnuts/day (2-3% of total calories from ALA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Control Diet
Description: 2-3% ALA but no walnuts provided

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low ALA Diet
Description: ALA replaced by oleic acid
Study: NCT02789306

Intervention type: PROCEDURE
Intervention: Epidemiological study on the incidence of peri-implantitis
Description: Clinical and radiographic examination in the routine based protocol

Intervention type: PROCEDURE
Intervention: Epidemiological study on the incidence of peri-implantitis
Description: Clinical and radiographic examination in the routine based protocol
Study: NCT01540175

Intervention type: OTHER
Intervention: Blood samples obtained
Description: Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
Study: NCT00096395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT03913507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macroduct® Advanced Model 3710 SYS, Wescor
Description: for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
Study: NCT00096395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03082781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NCDsport
Description: Negative Calorie Diet supplemented with exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCDsport
Description: Low-Calorie diet with exercise
Study: NCT02142244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infra red sentinel node biopsy
Description: Explicated in the protocol arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Explicated in the protocol arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Near-Infrared Imaging System
Description: Explicated in the protocol arm
Study: NCT03823300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
Study: NCT01134081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CelTx™
Description: CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.